Enlivex Therapeutics (ENLV) Competitors $1.16 +0.03 (+2.30%) As of 11:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. CRDL, ATOS, QNTM, CCCC, CRBP, OPTN, FBRX, SAVA, TNYA, and VIRIShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Cardiol Therapeutics (CRDL), Atossa Genetics (ATOS), Quantum Biopharma (QNTM), C4 Therapeutics (CCCC), Corbus Pharmaceuticals (CRBP), OptiNose (OPTN), Forte Biosciences (FBRX), Cassava Sciences (SAVA), Tenaya Therapeutics (TNYA), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Its Competitors Cardiol Therapeutics Atossa Genetics Quantum Biopharma C4 Therapeutics Corbus Pharmaceuticals OptiNose Forte Biosciences Cassava Sciences Tenaya Therapeutics Virios Therapeutics Enlivex Therapeutics (NASDAQ:ENLV) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk. Which has stronger earnings and valuation, ENLV or CRDL? Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.75Cardiol TherapeuticsN/AN/A-$26.77M-$0.34-4.31 Is ENLV or CRDL more profitable? Enlivex Therapeutics' return on equity of -57.67% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -57.67% -50.52% Cardiol Therapeutics N/A -209.63%-141.09% Do analysts prefer ENLV or CRDL? Enlivex Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 765.05%. Cardiol Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 446.08%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Cardiol Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more volatility & risk, ENLV or CRDL? Enlivex Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Do insiders & institutionals hold more shares of ENLV or CRDL? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer ENLV or CRDL? In the previous week, Enlivex Therapeutics' average media sentiment score of 1.87 beat Cardiol Therapeutics' score of 0.93 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Enlivex Therapeutics Very Positive Cardiol Therapeutics Positive SummaryEnlivex Therapeutics beats Cardiol Therapeutics on 7 of the 10 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.34M$2.41B$5.49B$9.01BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-1.758.9626.7120.06Price / SalesN/A668.82419.59119.24Price / CashN/A151.5836.1356.90Price / Book1.164.628.065.59Net Income-$15.01M$31.34M$3.16B$248.50M7 Day Performance-4.46%0.64%1.81%2.67%1 Month Performance22.94%7.64%3.99%5.49%1 Year Performance-13.08%1.44%35.40%21.00% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.3429 of 5 stars$1.16+2.3%$10.00+765.1%-14.4%$27.34MN/A-1.7570CRDLCardiol Therapeutics2.5261 of 5 stars$1.28+3.2%$8.67+577.1%-29.1%$102.49MN/A-3.7620Positive NewsGap UpATOSAtossa Genetics2.1927 of 5 stars$0.80+1.3%$6.17+670.8%-27.8%$102.04MN/A-3.818Positive NewsQNTMQuantum BiopharmaN/A$23.01-34.3%N/AN/A$101.76MN/A-1.44N/ACCCCC4 Therapeutics2.0262 of 5 stars$1.47+3.5%$12.00+716.3%-66.4%$100.83M$35.58M-1.00150CRBPCorbus Pharmaceuticals3.9189 of 5 stars$7.89-4.2%$50.88+544.8%-83.9%$100.83MN/A-1.8740OPTNOptiNose0.6866 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190FBRXForte Biosciences3.1054 of 5 stars$12.76-13.0%$61.00+378.1%+65,943.1%$96.51MN/A-0.785Gap UpHigh Trading VolumeSAVACassava Sciences4.2092 of 5 stars$1.89-5.0%$54.50+2,783.6%-83.0%$96.13MN/A-1.2630News CoverageTNYATenaya Therapeutics3.4436 of 5 stars$0.56-4.9%$6.25+1,018.9%-79.4%$95.50MN/A-0.48110VIRIVirios TherapeuticsN/A$4.90+2.1%$5.00+2.0%+2,015.4%$94.36MN/A-18.155 Related Companies and Tools Related Companies CRDL Competitors ATOS Competitors QNTM Competitors CCCC Competitors CRBP Competitors OPTN Competitors FBRX Competitors SAVA Competitors TNYA Competitors VIRI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
